Boosting natural killer cell therapy in glioblastoma
Goldman DRG engineers new drugs that improve activity of adoptive NK cells for GBM
Goldman DRG engineers new drugs that improve activity of adoptive NK cells for GBM
Partnership with Cannex Scientific to study novel drugs for neuro-psychiatry and tissue injury
Published in a 2020 issue of iScience, the DRG uncover mechanisms that drive response or resistance to cancer immunotherapy
The DRG publishes an article in Cancer Research describing a novel nanotherapeutic that can re-active natural killer cells and improve killing of adoptive cell therapies